NOVO NORDISK : Buy rating from UBS

Published on 2025-06-06 at 11:10

MarketScreener with dpa-AFX Analyser

UBS is positive on the stock with a Buy rating. The target price is unchanged at DKK 700.

Latest news about Novo Nordisk A/S

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says	06:15am	RE
NOVO NORDISK : UBS lowers target price	04:55am
Berenberg Keeps Novo Nordisk at Hold Amid Wegovy Volume Growth Data Focus	03:00am	MT
NOVO NORDISK : Receives a Buy rating from UBS	01:07am	ZD
European shares fall on healthcare, financials drag; focus on US-EU trade deal	07-15	RE
European shares fall on healthcare, financials drag; focus on US-EU trade deal	07-15	RE
Kailera touts late-stage win for weight-loss drug in China	07-15	RE
Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales	07-15	FW
NOVO NORDISK : Berenberg sticks Neutral	07-15	ZD
Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	07-14	FW
Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	07-14	MT
Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	07-13	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
NOVO NORDISK : Gets a Buy rating from UBS	07-11	ZD
Wall Street Waits to Hear the Numbers	07-11
Mining, healthcare prop up European shares; US-EU trade talks in focus	07-10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
European shares close at four-week high on banks boost; US trade talks in focus	07-09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	07-09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	07-09	ZD
Europe rises despite new US tariff mayhem	07-09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT